Thank you for being part of something genuinely important. You are one of a small group of women invited to participate in the inaugural Sovereign ECS pilot study — a carefully designed programme exploring the role of natural, broad-spectrum phytocannabinoid suppositories in supporting hormonal balance, emotional wellbeing, and whole-body comfort during one of the most significant natural transitions a woman's body can experience.
This is not a pharmaceutical trial. There are no synthetic hormones. No side effects to manage. No dependency to worry about. What we are doing is far simpler — and, we believe, far more powerful: we are giving your body the natural tools it already understands.
Through the natural activation of your endocannabinoid system, Sovereign ECS suppositories are designed to support your body's own ability to regulate mood, sleep, pain sensitivity, and hormonal signalling during this natural transition. We are not trying to override your biology. We are working with it — supporting the system that was always designed to bring you back to balance.
Every woman's experience of perimenopause and menopause is different. This study will help us understand how natural phytocannabinoid support changes that experience — and for whom it works best.
These two questionnaires are the foundation of the pilot study. Your honest responses — before, during, and after use — are what make the data meaningful. Each takes approximately 5 minutes to complete.
Complete this before you take your first suppository. This is your personal baseline — recording how you feel across all eight measured areas before the study begins.
It is completed once only. Without this baseline, the follow-up data has no point of comparison — so please complete it first.
Complete this at the end of each week for four consecutive weeks — beginning after your first week of use. The same questionnaire is used each time.
Weeks 3 and 4 continue after your suppository supply ends. This allows us to understand whether the natural effects are sustained once active use has finished.
Tip: Set a recurring reminder on your phone for the same time each evening — 30 minutes before sleep is ideal. Consistency in timing makes the data more meaningful and takes the guesswork out of the routine.
Inside every human body is a biological network that most women — and most doctors — have never been told about. It is called the endocannabinoid system (ECS).
Receptors are found throughout the brain, nervous system, immune tissue, reproductive organs, skin, and gut. Its primary function is homeostasis — the constant, natural work of keeping your body in balance.
When the ECS is well-supported, research suggests it plays a meaningful role across a broad range of physiological functions relevant to hormonal health:
During perimenopause and menopause, estrogen and progesterone levels fluctuate and decline. These hormones interact directly with ECS receptor expression — meaning that as hormone levels shift during this natural transition, ECS function can become dysregulated.
This dysregulation contributes to disrupted sleep, mood changes, temperature sensitivity, joint discomfort, brain fog, and reduced libido. Supporting the ECS during this natural transition is not about replacing hormones. It is about restoring the body's own natural regulatory capacity — activating the system that was always designed to manage these signals.
This is what Sovereign ECS is formulated to do — working with your body's own natural regulatory capacity, not against it.
Sovereign ECS suppositories contain a natural, broad-spectrum phytocannabinoid complex derived from hemp — including CBG, CBN, CBDa, CBL, and additional minor cannabinoids working together through the entourage effect.
Unlike CBD isolate products, which contain only a single compound, the Sovereign ECS formulation is designed to interact with both CB1 receptors (brain, nervous system, and reproductive tissue) and CB2 receptors (immune tissue, skin, and gastrointestinal tract) simultaneously. CBD isolate does not bind directly to either receptor. It requires a full cannabinoid complex to activate the ECS properly.
The suppository format provides direct natural absorption through the rectal mucosa, bypassing first-pass liver metabolism and delivering phytocannabinoids directly to the pelvic region — where CB1 and CB2 receptors are densely expressed in the uterus, ovaries, and surrounding tissue.
THC-free, non-psychoactive, and entirely free of synthetic hormones. No detectable THC. Safe for women who cannot or choose not to use hormone replacement therapy.
Most people encountering cannabinoids for the first time assume that CBD and THC are what the body needs. This is a reasonable assumption given how dominant both are in public conversation — but it reflects marketing and legislation more than pharmacology.
CBD isolate is a single extracted compound. On its own, it does not bind directly to CB1 or CB2 receptors — the primary receptor sites of the endocannabinoid system. It exerts indirect influence through other pathways, including TRPV1 and 5-HT1A, which have value but represent only a narrow slice of what the ECS is capable of when properly supported. A single compound cannot activate a system designed to respond to dozens of them working together. Using CBD isolate to support the ECS is a little like pressing one key on a piano and calling it music.
THC does bind directly to CB1 receptors and produces measurable effects, but it is psychoactive, federally restricted, and carries legal and employment risk for many women. More significantly for this context, the psychoactive effect of THC is itself a sign of receptor overstimulation — the CB1 receptor was not designed to be flooded with an external agonist at the concentrations found in THC-dominant products. Chronic high-dose THC use is associated with CB1 receptor downregulation — the body's response to being overwhelmed — which over time can actually reduce ECS sensitivity rather than support it.
The Sovereign ECS formulation contains no detectable THC and no CBD isolate. Instead, it delivers twelve naturally occurring cannabinoids from broad-spectrum hemp distillate — each interacting with different receptor sites, different signalling pathways, and different physiological systems. This is how the ECS was designed to be supported: not with a single overwhelming compound, but with a diverse complement of plant-based molecules that mirror the complexity of the system itself.
A note on the source plant. Hemp and cannabis are the same botanical species — Cannabis sativa L. — but they are legally and compositionally distinct. Hemp is defined under the 2018 Farm Bill as cannabis containing no more than 0.3% THC by dry weight. Everything in the Sovereign ECS formulation is derived entirely from hemp, not from high-THC cannabis. This matters for three reasons. First, it means there is no psychoactive risk — the plant itself contains negligible THC before any processing. Second, it means full federal legal compliance, with no legal or employment risk for participants. Third, and most importantly for the formulation, hemp grown for broad-spectrum distillate is cultivated specifically to express a rich and diverse cannabinoid profile — the same molecules found in cannabis, but without the THC dominance that makes high-THC cannabis an unsuitable source for this kind of precision wellness formulation. The cannabinoids in this product come from a plant, not a laboratory. They are the same compounds your body's endocannabinoid system evolved alongside.
The entourage effect describes the synergistic interaction between multiple cannabinoids and plant compounds — producing a combined effect greater than any single compound in isolation. This is a foundational principle of Sovereign ECS formulation design.
These suppositories are designed for gentle, shallow rectal insertion — they do not need to be inserted deeply. With clean hands, gently insert the suppository just inside the rectal opening. The natural mucosal tissue at this level absorbs the phytocannabinoids directly and efficiently.
Insert before sleep and allow your body to do the rest naturally. A simple phone reminder 30 minutes before sleep takes the guesswork out of the routine.
We are interested in how you feel — naturally and honestly — across a range of areas that matter to women during perimenopause and menopause. The questionnaires are designed to capture meaningful, real-world changes.
Every ingredient in the Sovereign ECS suppository has been chosen with purpose. The base carries the phytocannabinoids efficiently to the mucosal tissue. The cannabinoid complex does the work. Nothing else is added.
The primary suppository base. Cocoa butter is solid at room temperature and melts precisely at body temperature, releasing the phytocannabinoid complex directly at the rectal mucosa for immediate local absorption. It is naturally emollient, well-tolerated by sensitive tissue, and has been used as a pharmaceutical suppository base for over a century. Organically sourced.
A secondary carrier that enhances cannabinoid solubility and absorption. Coconut oil is rich in medium-chain triglycerides (MCTs), which are highly compatible with lipophilic cannabinoid molecules — helping them cross mucosal membranes efficiently. It also carries natural antimicrobial and anti-inflammatory properties that are well suited to the pelvic mucosal environment. Cold-pressed, virgin, organically sourced.
A nutritive carrier oil that complements the cannabinoid complex. Hemp seed oil contains no cannabinoids itself but is exceptionally rich in omega-3 and omega-6 essential fatty acids in an ideal 3:1 ratio, as well as gamma-linolenic acid (GLA) — an omega-6 fatty acid with well-documented anti-inflammatory activity directly relevant to the hormonal transition. GLA has been associated in research with supporting hormonal balance and reducing inflammation linked to estrogen fluctuation. It also provides vitamin E, supporting mucosal tissue health at the site of absorption.
The following cannabinoids are present in the broad-spectrum phytocannabinoid complex as confirmed across both the finished product and source distillate Certificates of Analysis. Each plays a distinct role in supporting the endocannabinoid system during hormonal transition.
CBD is the most abundant cannabinoid in the formulation and the foundation of its activity. It interacts with CB1 and CB2 receptors indirectly and activates TRPV1, 5-HT1A, and PPARgamma pathways — all of which are relevant to the hormonal transition experience. In the context of perimenopause and menopause, CBD has been associated in research with supporting anxiolytic activity relevant to mood instability, modulation of pain signalling relevant to joint discomfort and pelvic pain, support of sleep onset and sleep quality through 5-HT1A interaction, and thermoregulatory signalling relevant to hot flush frequency and intensity. It is non-psychoactive, THC-free, and well-tolerated.
CBG is the biosynthetic precursor from which most other cannabinoids are derived, and it acts directly on CB1 and CB2 receptors as well as alpha-2 adrenoreceptors. It has demonstrated anti-inflammatory activity in preclinical research that is particularly relevant to the systemic low-grade inflammation associated with estrogen decline. CBG may support bladder function and pelvic floor tone, areas directly affected during the menopause transition. Its neuroprotective properties are also relevant to the cognitive clarity and brain fog symptoms commonly reported during this period.
CBN is a mildly psychoactive cannabinoid formed through the natural oxidation of THC, though at these concentrations it produces no meaningful psychoactive effect. It has the strongest association in cannabinoid research with sedative properties, making it directly relevant to the sleep disruption that is one of the most commonly reported and debilitating symptoms of menopause. CBN also interacts with TRPV2 receptors involved in pain signalling, and early research suggests it may support bone density — an important consideration given the accelerated bone loss associated with estrogen decline post-menopause.
CBC does not bind directly to CB1 or CB2 receptors but interacts with TRPA1 and TRPV1 channels involved in pain and inflammation. Research has linked CBC to neurogenesis — the growth of new brain cells — which is relevant to the cognitive symptoms of menopause including memory disruption and brain fog. CBC also demonstrates synergistic anti-inflammatory activity alongside CBD, amplifying the overall anti-inflammatory effect of the formulation through the entourage effect.
CBDa is the undecarboxylated precursor to CBD and is increasingly recognised as having distinct biological activity rather than being simply an inactive precursor. It is a potent COX-2 inhibitor — the same enzyme targeted by common non-steroidal anti-inflammatory drugs — which is directly relevant to the inflammatory pain and joint discomfort of the menopause transition. CBDa has also demonstrated strong anti-nausea activity in preclinical models through 5-HT1A activation, and preliminary evidence suggests it may have higher bioavailability than CBD itself via certain delivery routes.
CBGa is the acidic precursor form of CBG and is a PPARgamma agonist — a receptor pathway involved in fat metabolism, insulin sensitivity, and inflammatory regulation. PPARgamma activation is particularly relevant during the menopause transition, when metabolic changes including central adiposity and insulin resistance become more common. CBGa's anti-inflammatory properties contribute to the overall formulation effect on systemic inflammation driven by estrogen withdrawal.
CBDV is a homologue of CBD with structural similarities and overlapping but distinct receptor activity. It is a potent TRPV1 modulator with anti-convulsant and anti-nausea properties in preclinical research. In the context of women's hormonal health, CBDV's activity on the TRPV1 channel — which is involved in both pain transmission and thermoregulation — is relevant to hot flush signalling and pelvic pain. It also contributes to the overall anxiolytic profile of the formulation.
CBE is a metabolite of CBD formed through enzymatic oxidation, and is present as a natural component of the broad-spectrum distillate. It interacts with CB2 receptors expressed in immune tissue, making it relevant to the immune dysregulation that can accompany estrogen decline during the menopause transition. Emerging research suggests CBE may also have hepatoprotective properties, supporting the liver's role in estrogen metabolism and clearance — a pathway that becomes particularly important when endogenous hormone levels are fluctuating. It contributes to the overall entourage effect of the formulation.
CBT is a naturally occurring minor cannabinoid found in hemp distillate. Research into its specific pharmacology is at an early stage, but CBT has demonstrated antioxidant activity in preclinical models. Oxidative stress is an important and underappreciated factor in the menopause transition, as declining estrogen reduces the body's natural antioxidant defences — contributing to cardiovascular risk, skin ageing, and systemic inflammation. CBT's presence in the formulation contributes to the broader antioxidant and entourage profile of the cannabinoid complex.
CBNA is the undecarboxylated precursor to CBN and carries its own distinct biological activity. Like other cannabinoid acids, it interacts with PPARgamma receptors involved in inflammatory regulation and metabolic signalling — pathways highly relevant to the hormonal changes of perimenopause and menopause. CBNA also contributes to the acid-form entourage effect alongside CBDa and CBGa, supporting the formulation's anti-inflammatory profile at a systemic level.
CBL is a naturally occurring minor cannabinoid formed through the photochemical conversion of CBC. It is one of the most chemically stable cannabinoids and has demonstrated antioxidant activity in preclinical research. While its direct receptor pharmacology is not yet fully characterised, CBL contributes to the overall broad-spectrum entourage effect. Its stability also makes it a reliable marker of formulation integrity — its presence confirms the authenticity and completeness of the broad-spectrum hemp extract.
9(S)-HHCH is a naturally occurring hydrogenated form of cannabinol present in trace amounts in the broad-spectrum distillate. It is structurally related to HHC and shares some receptor binding characteristics with THC, binding CB1 and CB2 receptors with moderate affinity. At the concentrations present in this formulation, it is non-psychoactive but contributes analgesic and anxiolytic properties to the entourage effect. Its relevance to women's hormonal health lies in its potential to support pain modulation and mood stability — two of the most commonly reported areas of difficulty during perimenopause and menopause.
Every batch of Sovereign ECS suppositories is independently tested by an accredited third-party laboratory. The cannabinoid profile below is taken directly from the Certificate of Analysis for the batch used in this pilot study.
Testing was performed by Bluebonnet Labs, Dallas, Texas (TX Registration TL2020031, ISO/IEC 17025:2017, Certificate 6400.01) using HPLC-PDA methodology. Lab ID: BBL_9485. Reported 20 January 2026.
The broad-spectrum distillate used in this formulation. Tested by Anresco Laboratories (ISO/IEC 17025:2017, ANAB AT-1551). Total THC: Not Detected. Total cannabinoids: 70.07%. Pesticide screen: Pass. Heavy metals: Pass. Residual solvents: Pass.
If you are currently taking hormone replacement therapy (HRT), prescribed medications, or have any ongoing medical conditions, please reach out to Barry Bonner directly before participating. Do not discontinue any prescribed medication without appropriate guidance. If you experience any unexpected reactions, discontinue use and contact Barry immediately.
Barry Bonner · barry@bonnerbiotech.com · +1 415 515 1665
"I spent 25 years in pharmaceutical and biotech development — working on autoimmune disease and cancer treatments at the highest levels of the industry. In 2017, I had a stroke. That event changed everything.
In the years that followed, I turned to the science I had been taught to ignore: the endocannabinoid system, the gut-brain axis, the natural intelligence of the body when it is properly supported. What I found was extraordinary.
Sovereign ECS was born from that research — and from conversations with women who had tried everything the conventional system offered and were still searching for something that felt natural, sustainable, and aligned with how their bodies actually work.
This pilot study is the beginning of something important. Thank you for being part of it."
We are grateful for your participation and your trust. Please reach out at any time if you have questions or concerns — there are no wrong questions.